NDAOPHTHALMICSOLUTION/DROPS1 Generic Approved
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
45/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSOPT PF is a fixed-dose combination ophthalmic solution containing dorzolamide hydrochloride (a carbonic anhydrase inhibitor) and timolol maleate (a non-selective beta-blocker) used to treat elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The dual mechanism reduces aqueous humor secretion through two distinct pathways, providing synergistic IOP reduction compared to monotherapy. Patients instill the drops twice daily into the affected eye(s).
$0.893MPart D
PeakEstablished product in peak commercial phase with modest Part D uptake; brand team likely focused on market maintenance and defensive strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COSOPT PF generates minimal job posting activity, reflecting its mature market status and modest commercial spend relative to competitors. Employment opportunities are concentrated in defensive brand management, field-based sales, and medical information roles.
Company
Worked on COSOPT PF at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.